Literature DB >> 20547100

Enterobacterial tumor colonization in mice depends on bacterial metabolism and macrophages but is independent of chemotaxis and motility.

Jochen Stritzker1, Stephanie Weibel, Carolin Seubert, Andreas Götz, Achim Tresch, Nico van Rooijen, Tobias A Oelschlaeger, Philip J Hill, Ivaylo Gentschev, Aladar A Szalay.   

Abstract

Despite promising results and increasing attention in bacterial cancer therapy, surprisingly little is known about initial tumor colonization and the interaction between bacteria and surrounding tumor tissue. Here, we analyzed the role of chemotaxis, motility, and metabolism both in Escherichia coli and Salmonella enterica serovar Typhimurium strains upon intravenous injection into tumor-bearing mice. In contrast to previous models, we found that chemotaxis and motility do not play a significant role in tumor colonization and bacterial distribution within the tumor. Rather, the whole colonization and intratumoral migration process seems to be a passive mechanism that is influenced by the reticuloendothelial system of the host, by the tumor microenvironment and by the bacterial metabolism. These conclusions were supported by experimental data demonstrating that disruption of the basic branch of the aromatic amino acid biosynthetic pathway and depletion of macrophages, in contrast to flagellar mutations, led to significant changes in bacterial accumulation in tumors of live mice.
Copyright © 2010 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20547100     DOI: 10.1016/j.ijmm.2010.02.004

Source DB:  PubMed          Journal:  Int J Med Microbiol        ISSN: 1438-4221            Impact factor:   3.473


  14 in total

1.  Motility is critical for effective distribution and accumulation of bacteria in tumor tissue.

Authors:  Bhushan J Toley; Neil S Forbes
Journal:  Integr Biol (Camb)       Date:  2011-12-22       Impact factor: 2.192

2.  Magnetic resonance imaging of tumors colonized with bacterial ferritin-expressing Escherichia coli.

Authors:  Philip J Hill; Jochen Stritzker; Miriam Scadeng; Ulrike Geissinger; Daniel Haddad; Thomas C Basse-Lüsebrink; Uwe Gbureck; Peter Jakob; Aladar A Szalay
Journal:  PLoS One       Date:  2011-10-03       Impact factor: 3.240

3.  Efficiency of conditionally attenuated Salmonella enterica serovar Typhimurium in bacterium-mediated tumor therapy.

Authors:  Michael Frahm; Sebastian Felgner; Dino Kocijancic; Manfred Rohde; Michael Hensel; Roy Curtiss; Marc Erhardt; Siegfried Weiss
Journal:  MBio       Date:  2015-04-14       Impact factor: 7.867

Review 4.  Insights from 100 Years of Research with Probiotic E. Coli.

Authors:  Trudy M Wassenaar
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2016-09-29

5.  The genes slyA, STM3120 and htrA are required for the anticancer ability of VNP20009.

Authors:  Xiaoxin Zhang; Qiaoqiao Xu; Lirun Yang; Yueyang Lai; Zhuangzhuang Zhang; Chao Han; Chizhou Jiang; Jiahuang Li; Yixin Shi; Zi-Chun Hua
Journal:  Oncotarget       Date:  2016-12-06

6.  Draft Genome Sequence of the Tumor-Targeting Salmonella enterica Serovar Typhimurium Strain SL7207.

Authors:  Síle A Johnson; Michael J Ormsby; Daniel M Wall
Journal:  Genome Announc       Date:  2017-02-02

Review 7.  Salmonella-Mediated Cancer Therapy: An Innovative Therapeutic Strategy.

Authors:  Ze Mi; Zhi-Chao Feng; Cheng Li; Xiao Yang; Meng-Tian Ma; Peng-Fei Rong
Journal:  J Cancer       Date:  2019-08-20       Impact factor: 4.207

Review 8.  Targeted Cancer Therapy Using Engineered Salmonella typhimurium.

Authors:  Jin Hai Zheng; Jung-Joon Min
Journal:  Chonnam Med J       Date:  2016-09-23

9.  Effect of Salmonella enterica serovar Typhimurium VNP20009 and VNP20009 with restored chemotaxis on 4T1 mouse mammary carcinoma progression.

Authors:  Sheryl L Coutermarsh-Ott; Katherine M Broadway; Birgit E Scharf; Irving C Allen
Journal:  Oncotarget       Date:  2017-05-16

Review 10.  Cancer Immunotherapy: Priming the Host Immune Response with Live Attenuated Salmonella enterica.

Authors:  Marco Antonio Hernández-Luna; Rosendo Luria-Pérez
Journal:  J Immunol Res       Date:  2018-09-13       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.